Nanomix Corporation announced an agreement with Mobility Health, whereby Nanomix and Mobility Health plan to collaborate in the development of an LDT (Lab Developed Test) that can be deployed in a fully mobile lab to evaluate levels of circulating antibodies to COVID-19. Nanomix plans to supply the product elements and Mobility Health plans to complete development and validation of the test, with plans to file for a CLIA Lab Emergency Use Authorization (EUA) with the FDA.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -.--% | -.--% | -.--% |
2023 | Nanomix Corporation Announces Chief Executive Officer Changes | CI |
2023 | Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 4.9K | |
+4.36% | 32.47B | |
+16.51% | 7.45B | |
+22.05% | 3.89B | |
-16.29% | 3.17B | |
-25.96% | 1.28B | |
-36.14% | 1.09B | |
-35.42% | 902M | |
-0.13% | 893M | |
-24.12% | 857M |
- Stock Market
- Equities
- NNMX Stock
- News Nanomix Corporation
- Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies